← All trials
NCT06088082
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 1, 2023
- Primary completion
- Apr 1, 2024
- Completion date
- Apr 20, 2024
- First posted
- Oct 18, 2023
- Last posted
- Oct 18, 2023
- Enrollment
- 100
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- King Saud UniversityLead sponsor
- King Saud UniversityOverall official - principal investigator
- King Saud UniversityReponsible party - principal investigator
Drugs studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.